Influenza season: overseas anti-influenza prescription drug recommendations and market trend analysis

Oseltamivir (Tamiflu) : Produced by Swiss pharmaceutical company Roche, as a neuraminidase inhibitor antiviral drug, it occupies an important position in the global anti-influenza field and is currently one of the most widely used anti-influenza drugs in the world. It has good therapeutic and preventive effects on both influenza A and B, and is suitable for a wide range of people, including the treatment of influenza A and B in adults and children aged 1 year and over, and the prevention of influenza A and B in adults and adolescents aged 13 years and over. It has obvious advantages, not only has few side effects, but also has a wide age span and a low overall drug resistance rate. Usually adults take two pills a day, and they need to take it continuously for 5 days when treating influenza, and they cannot exceed 10 days when used to prevent influenza. Its large number of clinical studies and practical experience have fully confirmed that oseltamivir is effective in shortening the course of influenza, alleviating symptoms, and reducing the risk of complications. Therefore, it is widely recommended by authoritative guidelines at home and abroad.

Mabaloxavir (Sufuda) : Developed and produced jointly by Swiss Roche Pharmaceuticals and Japanese Shionogi Pharmaceuticals, it is an RNA polymerase inhibitor antiviral drug and is the first and only single-dose oral anti-influenza A and B drug approved for the treatment of influenza. It is suitable for previously healthy adults and children aged 5 years and above with simple influenza A and B, or adults and children aged 12 years and above with influenza who are at high risk of influenza-related complications. Just one oral dose can stop viral detoxification in about 24 hours, quickly shorten the infection period, and quickly relieve influenza symptoms such as fever and body aches. Although mabaloxavir is easy to take and quick to work, there are also some potential risks, such as long residence time in the body, difficulty in dealing with adverse reactions, and the risk of drug resistance, so be sure to strictly follow the doctor's advice when using it.

Peramivir : A new type of anti-influenza virus drug developed by Shionogi Pharmaceutical Co., Ltd. of Japan. It is also a neuraminidase inhibitor, which inhibits the neuraminidase activity of influenza virus and prevents the virus from being released and spread from infected cells. It is suitable for the treatment of influenza A and B in adults and children, especially for patients with severe influenza or those who cannot take the drug orally. It is an effective treatment option. However, it is administered by intravenous injection, which generally needs to be performed by professional medical staff in the hospital. Although clinical studies have shown that peramivir has good efficacy and safety in the treatment of influenza, due to its relatively high price and the need for certain medical conditions, its current clinical application is relatively less than oseltamivir and mabaloxavir.

Zanamivir : Produced by GlaxoSmithKline in the UK, it is an inhaled neuraminidase inhibitor, mainly used to treat influenza A and B in adults and children over 7 years old. It can act directly on the respiratory tract through inhalation and quickly inhibit the replication and spread of influenza viruses. Its advantages are strong local effects and relatively small systemic side effects, but for some patients with respiratory diseases or unable to use the inhalation device correctly, the use of zanamivir may be subject to certain restrictions. In addition, the price of zanamivir is relatively high, which has also affected its market promotion and application to a certain extent.